Author

Mauro Moroni

Ospedale San Carlo - Cited by 4,095 - Oncologia

Biography

Mauro Moroni is working as researcher in the Institute of Infectious and Tropical Diseases, University of Milan, Italy. Mauro Moroni International experience includes various programs, contributions and participation in different countries for diverse fields of study Mauro Moroni interests reflect in wide range of publications in various national and international journals. He is doing his research work in Microbiology, Vaccines, Immunotherapy, Ebola Virus.
Title
Cited by
Year
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ...The lancet oncology 6 (5), 279-286, 2005200
1149
2005
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies
S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ...Cancer research 67 (6), 2643-2648, 2007200
1044
2007
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
A Sartore-Bianchi, M Moroni, S Veronese, C Carnaghi, E Bajetta, G Luppi, ...Journal of Clinical Oncology 25 (22), 3238-3245, 2007200
392
2007
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus–targeted cytotoxic T lymphocytes
P Comoli, P Pedrazzoli, R Maccario, S Basso, O Carminati, M Labirio, ...Journal of Clinical Oncology 23 (35), 8942-8949, 2005200
286
2005
Altered expression of heterogeneous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas
C Ghigna, M Moroni, C Porta, S Riva, G BiamontiCancer Research 58 (24), 5818-5824, 1998199
112
1998
In vitro antioxidant properties of amifostine (WR-2721, Ethyol)
F Marzatico, C Porta, M Moroni, L Bertorelli, E Borasio, N Finotti, ...Cancer chemotherapy and pharmacology 45 (2), 172-176, 2000200
101
2000
Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study
E Bobbio-Pallavicini, C Porta, M Moroni, G Bertulezzi, L Civelli, ...European Journal of Cancer 33 (11), 1784-1788, 1997199
75
1997
Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors
M Moroni, S Veronese, R Schiavo, O Carminati, BS Sorensen, ...Clinical cancer research 7 (9), 2770-2775, 2001200
68
2001
Endothelin-1 and 5-fluorouracil-induced cardiotoxicity.
C Porta, M Moroni, S Ferrari, G NastasiNeoplasma 45 (2), 81-82, 1997199
60
1997
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study
A Sartore-Bianchi, S Fieuws, S Veronese, M Moroni, N Personeni, ...Journal of clinical pathology 65 (3), 218-223, 2012201
52
2012
EGFR FISH in colorectal cancer: what is the current reality?
M Moroni, A Sartore-Bianchi, S Veronese, S SienaThe lancet oncology 9 (5), 402-403, 2008200
50
2008
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer
M Moroni, A Sartore-Bianchi, S Benvenuti, S Artale, A Bardelli, S SienaAnnals of oncology 16 (11), 1848-1849, 2005200
39
2005
Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients
M Moroni, C Porta, M De Amici, S Quaglini, MA Cattabiani, C BuzioHaematologica 85 (3), 298-303, 2000200
28
2000
Interleukin‐2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro
C Porta, M Danova, AM Orengo, S Ferrini, M Moroni, A Gaggero, ...Journal of cellular Physiology 185 (1), 126-134, 2000200
24
2000
Cetuximab for treatment of metastatic colorectal cancer
G Cerea, R Ricotta, I Schiavetto, MR Maugeri, A Sartore-Bianchi, ...Annals of Oncology 17 (suppl 7), vii66-vii67, 2006200
22
2006
Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab
R Ricotta, A Vanzulli, M Moroni, B Colnago, M Oriani, M Nichelatti, ...Clinical colorectal cancer 12 (1), 45-53, 2013201
15
2013
Epidermal growth factor receptor gene copy number
S Siena, M Moroni, A BardelliUS Patent 7,635,570, 2009200
15
2009
EOSINOPHILS AND SERUM EOSINOPHILIC CATIONIC PROTEINS IN INTERLEUKIN‐2‐BASED IMMUNOTHERAPY FOR CANCER
C Porta, M Moroni, M De AmiciBritish journal of haematology 100 (3), 607-608, 1998199
13
1998
Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated …
M Moroni, L Giannetta, G Gelosa, S Secondino, G Chillura, E Colombo, ...Journal of chemotherapy 15 (4), 394-399, 2003200
13
2003
‘Tunel’evidence of reduced bone marrow cells apoptosis in a refractory anaemia patient treated with amifostine
M Moroni, C Porta, R Invernizzi, A Inzoli, F Bobbio‐Pallavicini, ...British journal of haematology 4 (2), 424-425, 1999199
10
1999

Referred From: https://scholar.google.com/citations?hl=en&user=bJ-AT_IAAAAJ

Cited by
Citations 4095
h-index 20
i10-index 31
Recommended Journals
Open Access Journals